Published in Nat Struct Mol Biol on December 13, 2009
Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science (2010) 2.98
CpG islands recruit a histone H3 lysine 36 demethylase. Mol Cell (2010) 2.86
Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell (2010) 2.25
Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development (2012) 2.24
The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol Cell (2010) 2.06
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res (2010) 1.77
MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood (2011) 1.74
Coordinated chromatin control: structural and functional linkage of DNA and histone methylation. Biochemistry (2010) 1.74
Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature (2013) 1.65
Kdm2b maintains murine embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes. Nat Cell Biol (2013) 1.61
Molecular coupling of DNA methylation and histone methylation. Epigenomics (2010) 1.43
The structural basis for selective binding of non-methylated CpG islands by the CFP1 CXXC domain. Nat Commun (2011) 1.37
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov (2012) 1.33
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood (2012) 1.31
ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection. Biochem Soc Trans (2013) 1.30
A novel non-SET domain multi-subunit methyltransferase required for sequential nucleosomal histone H3 methylation by the mixed lineage leukemia protein-1 (MLL1) core complex. J Biol Chem (2010) 1.21
TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev (2015) 1.18
Synthetic CpG islands reveal DNA sequence determinants of chromatin structure. Elife (2014) 1.13
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer (2015) 1.12
Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev (2016) 1.08
Structural and functional coordination of DNA and histone methylation. Cold Spring Harb Perspect Biol (2014) 0.98
Crystal structure of the N-terminal region of human Ash2L shows a winged-helix motif involved in DNA binding. EMBO Rep (2011) 0.96
Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML. Leukemia (2013) 0.94
The mysterious presence of a 5-methylcytosine oxidase in the Drosophila genome: possible explanations. Cell Cycle (2013) 0.93
Selective targeting of histone methylation. Cell Cycle (2011) 0.92
Phosphorylation of Histone H2A at Serine 95: A Plant-specific Mark Involved in Flowering Time Regulation and H2A.Z Deposition. Plant Cell (2017) 0.91
Recognition of CpG island chromatin by KDM2A requires direct and specific interaction with linker DNA. Mol Cell Biol (2011) 0.89
MLL fusion proteins link transcriptional coactivators to previously active CpG-rich promoters. Nucleic Acids Res (2014) 0.86
Menin as a hub controlling mixed lineage leukemia. Bioessays (2012) 0.85
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discov (2016) 0.85
3'UTR-mediated gene silencing of the Mixed Lineage Leukemia (MLL) gene. PLoS One (2011) 0.84
Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Exp Hematol (2014) 0.84
Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. Cancers (Basel) (2012) 0.83
Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. J Biol Chem (2013) 0.81
RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes. Mol Cancer (2014) 0.80
p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Mol Oncol (2013) 0.80
Structural models of protein-DNA complexes based on interface prediction and docking. Curr Protein Pept Sci (2011) 0.80
Transcriptional repressor domain of MBD1 is intrinsically disordered and interacts with its binding partners in a selective manner. Sci Rep (2014) 0.79
Induction of activation-induced cytidine deaminase-targeting adaptor 14-3-3γ is mediated by NF-κB-dependent recruitment of CFP1 to the 5'-CpG-3'-rich 14-3-3γ promoter and is sustained by E2A. J Immunol (2013) 0.79
Introduction--Epiphanies in epigenetics. Prog Mol Biol Transl Sci (2011) 0.79
Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal. Blood (2014) 0.79
Discovery of MLL1 binding units, their localization to CpG Islands, and their potential function in mitotic chromatin. BMC Genomics (2013) 0.79
AF9 promotes hESC neural differentiation through recruiting TET2 to neurodevelopmental gene loci for methylcytosine hydroxylation. Cell Discov (2015) 0.78
Establishment of active chromatin structure at enhancer elements by mixed-lineage leukemia 1 to initiate estrogen-dependent gene expression. Nucleic Acids Res (2013) 0.78
Are there specific readers of oxidized 5-methylcytosine bases? Bioessays (2016) 0.78
EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas. Epigenetics (2015) 0.78
KDM2A integrates DNA and histone modification signals through a CXXC/PHD module and direct interaction with HP1. Nucleic Acids Res (2017) 0.77
The leukemogenic fusion gene MLL-AF9 alters microRNA expression pattern and inhibits monoblastic differentiation via miR-511 repression. J Exp Clin Cancer Res (2016) 0.77
Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4. Leuk Res (2014) 0.77
TBP loading by AF4 through SL1 is the major rate-limiting step in MLL fusion-dependent transcription. Cell Cycle (2016) 0.77
Retrotransposition creates sloping shores: a graded influence of hypomethylated CpG islands on flanking CpG sites. Genome Res (2015) 0.76
Hydroxymethylation of DNA: an epigenetic marker. EXCLI J (2014) 0.75
Solution structure of human MBD1 CXXC1. J Biomol NMR (2015) 0.75
MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. Cell Discov (2016) 0.75
A role for epigenetics in the formation of chromosome translocations in acute leukemia. Cancer Genet (2015) 0.75
The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1. Leuk Res (2016) 0.75
Not All H3K4 Methylations Are Created Equal: Mll2/COMPASS Dependency in Primordial Germ Cell Specification. Mol Cell (2017) 0.75
Fingerprinting acute leukemia: DNA methylation profiling of B-acute lymphoblastic leukemia. Cancer Discov (2012) 0.75
Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. Int J Biochem Mol Biol (2016) 0.75
CXXC5 expression in prostate cancer: implications for cancer progression. Int J Exp Pathol (2017) 0.75
Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation. Oncotarget (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR (1995) 93.94
AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR (1996) 29.55
Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR (1999) 26.99
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
Altered Hox expression and segmental identity in Mll-mutant mice. Nature (1995) 6.60
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell (2006) 6.34
Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell (1992) 6.11
Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A (2005) 5.53
Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell (2008) 4.20
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet (2001) 3.96
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell (2005) 3.70
Protein-DNA interactions: A structural analysis. J Mol Biol (1999) 3.38
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A (2005) 3.37
Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J (2006) 2.89
MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc Natl Acad Sci U S A (1998) 2.65
Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA. Cell (2001) 2.64
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res (2005) 2.45
The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res (2002) 2.43
Binding of trithorax and Polycomb proteins to the bithorax complex: dynamic changes during early Drosophila embryogenesis. EMBO J (1998) 2.34
Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood (2009) 2.11
Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol (2004) 1.94
Identification and characterization of the DNA binding domain of CpG-binding protein. J Biol Chem (2001) 1.93
Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J (2000) 1.87
MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci U S A (2003) 1.83
Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. Br J Haematol (1999) 1.78
Mbd1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains. Mol Cell Biol (2004) 1.74
Charged gels as orienting media for measurement of residual dipolar couplings in soluble and integral membrane proteins. J Am Chem Soc (2004) 1.63
MLL: how complex does it get? J Cell Biochem (2005) 1.61
The bithorax complex is regulated by trithorax earlier during Drosophila embryogenesis than is the Antennapedia complex, correlating with a bithorax-like expression pattern of distinct early trithorax transcripts. Development (1994) 1.58
The MLL recombinome of acute leukemias. Leukemia (2006) 1.51
MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci U S A (2008) 1.50
When epigenetics kills: MLL fusion proteins in leukemia. Hematol Oncol (2005) 1.46
Quantitative NMR studies of high molecular weight proteins: application to domain orientation and ligand binding in the 723 residue enzyme malate synthase G. J Mol Biol (2003) 1.33
HOX deregulation in acute myeloid leukemia. J Clin Invest (2007) 1.20
Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene (2008) 1.15
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. Am J Clin Pathol (2004) 1.12
Function of the Polycomb protein is conserved in mice and flies. Development (1995) 1.12
Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest (1994) 1.10
Kinetic and thermodynamic evidence for flipping of a methyl-CpG binding domain on methylated DNA. Biochemistry (2008) 0.87
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell (2004) 2.43
The DCX-domain tandems of doublecortin and doublecortin-like kinase. Nat Struct Biol (2003) 2.22
Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood (2009) 2.11
The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell (2006) 2.09
NMR solution structure of the integral membrane enzyme DsbB: functional insights into DsbB-catalyzed disulfide bond formation. Mol Cell (2008) 1.92
MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci U S A (2003) 1.83
Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res (2010) 1.77
CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood (2009) 1.74
Site-directed parallel spin-labeling and paramagnetic relaxation enhancement in structure determination of membrane proteins by solution NMR spectroscopy. J Am Chem Soc (2006) 1.73
Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase. Proc Natl Acad Sci U S A (2009) 1.63
Charged gels as orienting media for measurement of residual dipolar couplings in soluble and integral membrane proteins. J Am Chem Soc (2004) 1.63
MLL: how complex does it get? J Cell Biochem (2005) 1.61
Optimal mutation sites for PRE data collection and membrane protein structure prediction. Structure (2011) 1.55
MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci U S A (2008) 1.50
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun (2012) 1.49
Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J (2007) 1.44
Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem Biol (2007) 1.44
Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A (2010) 1.43
Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell (2007) 1.43
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood (2012) 1.31
The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci U S A (2005) 1.29
Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials. Trends Biochem Sci (2009) 1.21
High resolution structure of the HDGF PWWP domain: a potential DNA binding domain. Protein Sci (2005) 1.19
The binding of the PDZ tandem of syntenin to target proteins. Biochemistry (2006) 1.19
Increasing the accuracy of solution NMR structures of membrane proteins by application of residual dipolar couplings. High-resolution structure of outer membrane protein A. J Am Chem Soc (2006) 1.18
Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure (2012) 1.18
Mammalian septins nomenclature. Mol Biol Cell (2002) 1.16
Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem (2011) 1.16
Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development. J Biol Chem (2006) 1.15
Energetic contribution of residues in the Runx1 Runt domain to DNA binding. J Biol Chem (2003) 1.12
Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3. Proc Natl Acad Sci U S A (2012) 1.12
Structure, dynamics and function of the outer membrane protein A (OmpA) and influenza hemagglutinin fusion domain in detergent micelles by solution NMR. FEBS Lett (2003) 1.09
Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases. Proc Natl Acad Sci U S A (2010) 1.09
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest (2013) 1.08
CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium. Nat Struct Mol Biol (2004) 1.08
Structure-based discovery of a boronic acid bioisostere of combretastatin A-4. Chem Biol (2005) 1.07
Overexpression of Foxn1 attenuates age-associated thymic involution and prevents the expansion of peripheral CD4 memory T cells. Blood (2011) 1.06
Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PLoS One (2013) 1.05
Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. Cancer Res (2008) 1.04
On the mechanism of autoinhibition of the RhoA-specific nucleotide exchange factor PDZRhoGEF. BMC Struct Biol (2009) 1.04
Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited. Proc Natl Acad Sci U S A (2013) 1.02
A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer (2002) 1.01
Ash1l controls quiescence and self-renewal potential in hematopoietic stem cells. J Clin Invest (2015) 1.00
Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds. J Med Chem (2007) 1.00
Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. Blood (2009) 0.98
The PHD3 domain of MLL acts as a CYP33-regulated switch between MLL-mediated activation and repression . Biochemistry (2010) 0.94
Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis. Nat Struct Biol (2002) 0.92
alpha-Aminoalkylphosphonates as a tool in experimental optimisation of P1 side chain shape of potential inhibitors in S1 pocket of leucine- and neutral aminopeptidases. Eur J Med Chem (2005) 0.91
FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis. Hepatology (2014) 0.90
A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15. Oncogene (2003) 0.90
Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14). Oncogene (2003) 0.90
Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit. J Biol Chem (2003) 0.90
High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J Med Chem (2014) 0.89
The solution structure and dynamics of the DH-PH module of PDZRhoGEF in isolation and in complex with nucleotide-free RhoA. Protein Sci (2009) 0.89
Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev (2015) 0.88
Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB. Chem Biol (2010) 0.87
Dysregulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and hox gene expression in hematopoietic cells. Cancer Res (2013) 0.86
Probing the supramodular architecture of a multidomain protein: the structure of syntenin in solution. Structure (2005) 0.86
Structural and functional characterization of Runx1, CBF beta, and CBF beta-SMMHC. Blood Cells Mol Dis (2003) 0.85
Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell (2012) 0.84
The role of CBFbeta in AML1-ETO's activity. Blood (2009) 0.84
MQ-hCN-based pulse sequences for the measurement of 13C1'-1H1', 13C1'-15N, 1H1'-15N, 13C1'-13C2', 1H1'-13C2',13C6/8-1H6/8, 13C6/8-15N, 1H6/8-15N, 13C6-13C5, 1H6-13C5 dipolar couplings in 13C, 15N-labeled DNA (and RNA). J Biomol NMR (2002) 0.83
Monomeric TonB and the Ton box are required for the formation of a high-affinity transporter-TonB complex. Biochemistry (2013) 0.83
Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity. J Mol Biol (2010) 0.83
Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype. Cancer Res (2006) 0.82
Origins of the activity of PAL and LAP enzyme inhibitors: toward ab initio binding affinity prediction. J Am Chem Soc (2005) 0.82
Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. J Biol Chem (2013) 0.81
The DC-module of doublecortin: dynamics, domain boundaries, and functional implications. Proteins (2006) 0.81
MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets. Curr Drug Targets (2010) 0.81
A mutation in the S-switch region of the Runt domain alters the dynamics of an allosteric network responsible for CBFbeta regulation. J Mol Biol (2006) 0.81
p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Mol Oncol (2013) 0.80
Challenges and opportunities in targeting the menin-MLL interaction. Future Med Chem (2014) 0.79
A synthetic method for diversification of the P1' substituent in phosphinic dipeptides as a tool for exploration of the specificity of the S1' binding pockets of leucine aminopeptidases. Bioorg Med Chem (2007) 0.79
The role of HTS in drug discovery at the University of Michigan. Comb Chem High Throughput Screen (2014) 0.78
Inhibition of CDC25B phosphatase through disruption of protein-protein interaction. ACS Chem Biol (2014) 0.77
Exploring the Sn binding pockets in gingipains by newly developed inhibitors: structure-based design, chemistry, and activity. J Med Chem (2006) 0.77
Detection of disordered regions in globular proteins using ¹³C-detected NMR. Protein Sci (2012) 0.77
Glycogen synthase kinase-3 and leukemia: restoring the balance. Cancer Cell (2010) 0.76
Synthesis and evaluation of substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human breast cancer cell proliferation. Bioorg Med Chem (2004) 0.75
In memoriam: Janet D. Rowley, MD (April 5, 1925-December 17, 2013). Cancer Genet (2014) 0.75
Assignment of 1H, 13C and 15N resonances of the N-terminal microtubule-binding domain of human doublecortin. J Biomol NMR (2003) 0.75